To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

November 13, 2017

Today's Rundown

Featured Story

Novartis, already up on CRISPR, CAR-T, looks to new gene editing R&D

Novartis has penned a new deal with Homology Medicines as it looks to boost its already impressive R&D work in cell and gene therapy.

Top Stories

Arcus Biosciences gains meaty $107M with help from Google

Immuno-oncology startup Arcus Bioscience has got off another impressive round of funding, just over a year after emerging from stealth with $120 million.

Zymeworks pens $50M upfront, $1B-plus biobucks Janssen bispecific pact

Zymeworks must be spending a fortune on pens as it inks yet another deal, this time with Johnson & Johnson’s biotech unit.

[Sponsored] Looking Toward Abuse Deterrent Opioids

The complex and intertwined dual epidemics of poorly treated pain and opioid addiction require a combined, artful approach to secure the best possible results for patients.

Moving beyond Cas9, Excision licenses CRISPR gene editors

Excision BioTherapeutics has licensed recently discovered CRISPR gene editors from UC Berkeley. The deal gives Excision the exclusive right to use the Cas9 alternatives to treat infectious diseases.

CRISPR, Bayer JV tap CureVac for Cas9 mRNA constructs

CRISPR Therapeutics and its joint venture with Bayer have struck a deal with CureVac. The pact tasks CureVac with developing Cas9 mRNA constructs for use by CRISPR and joint venture Casebia Therapeutics in three in vivo gene-editing liver disease programs.

Bill Gates pledges $50M for Alzheimer’s disease fund

Billionaire Bill Gates has turned his philanthropic eye toward Alzheimer’s disease, with a $50 million investment in the U.K.-based Dementia Discovery Fund.

Concept buy Aquila inks immuno-oncology deal with Macrophage Pharma

Concept Life Sciences’ recent acquisition of Aquila BioMedical has quickly produced a return—an extended contract with Macrophage Pharma to support its preclinical immuno-oncology programs.

GI Dynamics loses CE mark over quality nonconformance

GI Dynamics has lost the right to sell its Type 2 diabetes and obesity device in the European Union. SGS, the notified body for EndoBarrier, pulled the CE Certificate of Conformity over the weekend in response to nonconformity to medical device quality management system standards.

Resources

[Whitepaper] Accessing Scientific Literature Doesn’t Have To Be Like Scaling A Mountain

SO CLOSE AND YET SO FAR. Is that how many documents seem to you? Getting what you want—when, where, and how you want it—can be a real pain. That’s why we created this concise guide to getting around the obstacles that stand between you and the information your organization needs. Download the whitepaper to learn more.

[Whitepaper] eClinical Landscape Study from Tufts Center for the Study of Drug Development

See the results from one of the largest, most in-depth surveys of clinical data management professionals on data management practices, performance, and challenges.

[Whitepaper] Modernize Quality Management

Gain a complete, real-time view of quality and streamline operations. Incorporate partners into processes for critical oversight and 30% greater efficiency, and transform cross-functional processes like change control.

[Whitepaper] DSM Looks to Challenge Traditional Stent Graft Materials with its Dyneema Purity® Membrane Edit

Discover DSM's Dyneema Purity® membrane, an effective and efficient material to construct stent grafts used in minimally invasive surgeries to treat both cardiovascular and peripheral arterial diseases.

[Whitepaper] Meeting the Challenge of Appropriate Safety Report Distribution

As clinical trials become more complex, safety document distribution to investigative sites has reached the point that demands a solution.

[Webinar] Discover tested and proven solutions to manage territory vacancies

December 5, 2017 | 2pm EST / 11am PST | Sponsored By Ashfield Healthcare

Join this webinar to learn methods that maintain and build sales momentum despite turnover.

[Whitepaper] Veeva 2017 Annual CRO Report: CROs lead the drive to a unified clinical model

CROs are leading an industry wide shift to modernize clinical systems and clinical trial processes.

[Webinar] Validating a 7 Day Membrane Filtration Sterility Test using Celsis®

Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols.

[Infographic] Evolution of Flexible Commercial Biologics Manufacturing

Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility.

[eBook] Developing Site-specifically Modified ADCs: Using a Chemoenzymatic Approach

Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology.

[Article] Optimizing titer and use of a specific enzyme for generating a fully processed antibody

Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing.

[Webinar] Within-Subject Clinical Trials: Intro to New Methods & Stat. Models

In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods.

Events

.